Progestogens or progestogen-releasing intrauterine systems for uterine fibroids

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Sangkomkamhang, Ussanee S ^a   Lumbiganon, Pisake ^b   Laopaiboon, Malinee ^c   Mol, Ben Willem J ^d  

^a KHON KAEN HOSPITAL   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; GONADORELIN AGONIST; HEMATIN; HEMOGLOBIN; LEUPRORELIN; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BODY WEIGHT GAIN; DRUG EFFICACY; HEADACHE; HUMAN; HYSTERECTOMY; MENSTRUATION; NAUSEA; PELVIC PAIN; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UTERUS MYOMA; DRUG EFFECT; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; LEIOMYOMA; META ANALYSIS; PATHOLOGY; UTERUS CANCER;

ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEIOMYOMA; LEUPROLIDE; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; MENSTRUATION; PREMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR BURDEN; UTERINE NEOPLASMS;

EID: 84875541619     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008994.pub2     Document Type: Review

References (47)

1. Inki P, Hurskainen R, Palo P, Ekholm E, Grenman S, Kivela A, et al.Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound in Obstetrics & Gynecology 2002;20(4):381-5.
2. Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. International Journal of Gynaecology and Obstetrics 2011;112(2):126-30.
3. Verspyck E, Marpeau L, Lucas C. Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2000;89:7-13.
4. Caird LE, West CP, Lumsden MA, Hannan WJ, Gow SM. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. Human Reproduction 1997;12(3):436-40.
5. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. Journal of Clinical Endocrinology and Metabolism 1993;76(5):1217-23.
6. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. International Journal of Gynaecology and Obstetrics 2007;114(12):1510-5.
7. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Reviews 2005;26(3):423-38.
8. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility 2007;87(6):1399-412.
9. Friedman AJ, Barbieri RL, Doubilet PM, Fine C, Schiff I. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertility and Sterility 1988;49(3):404-9.
10. Koh SC, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia. Journal of Thrombosis and Haemostasis 2007;5(1):133-8.
11. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, et al.CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology 2008;111(5):1129-36.
12. Magalhaes J, Magalhaes LB. European Journal of Contraception and Reproductive Health Care. The Hague Netherlands, 2010.
13. Palomba S, Sena T, Morelli M, Noia R, Zullo F, Mastrantonio P. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2002;102(2):199-201.
14. Rodriguez MI, Warden M, Darney PD. Intrauterine progestins, progesterone antagonists, and receptor modulators: a review of gynecologic applications. American Journal of Obstetrics and Gynecology 2010;May;202(5):420-8.
15. Scialli AR, Jestila KJ. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertility and Sterility 1995;64(2):313-20.
16. Siddiqui M, Hossain F, Banu L. Levonorgestrel intrauterine system Mirena: An update. Bangladesh Journal of Obstetrics and Gynecology 2008;23(1):25-31.
17. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecologic and Obstetric Investigation 2005;59(1):29-35.
18. West CP, Lumsden MA, Hillier H, Sweeting V, Baird DT. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Human Reproduction 1992;7(3):328-32.
19. Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, et al.Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism 2008;Dec;93(12):4664-71.
20. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, et al.Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Seminars in Reproductive Medicine 2010;May;28(3):260-73.
21. Andersen J, Grine E, Eng CLY, et al.Expression of connexin-43 in human myometrium and leiomyoma. American Journal of Obstetrics and Gynecology 1993;169:1266-76.
22. Andersen J. Factors in fibroid growth. Bailliere's Clinical Obstetrics and Gynaecology 1998;12:225-43.
23. Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyomas in a random sample of women aged 25-40 years. Acta Obstetricia et Gynecologica Scandinavica 2000;79:202-7.
24. Cramer SAP. The frequency of uterine leiomyomas. American Journal of Clinical Pathology 1990;90:453-8.
25. DavidM, Ebert AD. Treatment of uterine fibroids by embolization--advantages, disadvantages, and pitfalls. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2005;123:131-8.
26. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
27. FIGO. The International Federation of Gynecology and Obstetrics. Internet 2001.
28. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environmental Health Perspectives 2003;111:1037-54.
29. Higgins JPT, Altman DG, Sterne JC, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for SystematicReviews of Interventions Version 5.1.0 [updated March2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
30. Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. Contraception 2007;75(6 Suppl):S130-3. Epub 2007 Mar 9.
31. Lethaby A, Cooke I, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858]
32. Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study. British Journal of Obstetrics and Gynaecology 1996;103(9):909-14.
33. Maruo T, Matsuo H, Samoto T, Shimomura Y, Kurachi O, Gao Z, et al.Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000;65(10-11):585-92.
34. Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstetrics and Gynecology Clinics of North America 2006;33:59-67.
35. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Human Reproduction Update 2004;10(3):207-20.
36. Maruo T, Ohara N, Matsuo H, Xu Q, Chen W, Sitruk-Ware R, Johansson ED. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 2007;75(6 Suppl):S99-103. Epub 2007 Mar 21.
37. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Practice & Research. Clinical Obstetrics & Gynaecology 2008;22(4):571-88.
38. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. American Journal of Obstetrics and Gynecology 1995 Jan;172(1 Pt 1):14-8.
39. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. International Journal of Gynecological Pathology 1986;5:235-41.
40. Singer A, Ikomi A. Successful treatment of fibroids using an intrauterine progesterone device. International Journal of Gynaecology and Obstetrics 1994;46:55.
41. Starczewski A, Iwanicki M. Intrauterine therapy with levonorgestrel-releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekologia Polska 2000;71:1221-5.
42. Stewart EA. Uterine fibroids. Lancet 2001;357:293-8.
43. Stovall DW. Clinical symptomatology of uterine leiomyomas. Clinical Obstetrics and Gynecology 2001;44:364-71.
44. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstetrics and Gynecology 2004;104:393-406.
45. Medical eligibility criteria for contraceptive use. WHO. Department of Reproductive Health and Research 2004.
46. United Nations Population Division. World Contraceptive Use 2005. wall chart. New York, NY: United Nations 2005.
47. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010;82(1):41-55.